{"id":11122,"date":"2026-03-06T02:18:18","date_gmt":"2026-03-06T02:18:18","guid":{"rendered":"https:\/\/pharmamachinecn.com\/?p=11122"},"modified":"2026-03-10T05:18:23","modified_gmt":"2026-03-10T05:18:23","slug":"what-is-regulatory-affairs-in-pharmaceutical-industry","status":"publish","type":"post","link":"https:\/\/pharmamachinecn.com\/tr\/what-is-regulatory-affairs-in-pharmaceutical-industry\/","title":{"rendered":"\u0130la\u00e7 Sekt\u00f6r\u00fcnde D\u00fczenleyici \u0130\u015fler Nedir?"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

D\u00fczenleyici \u0130\u015fler<\/span> <\/a>(RA) bir ila\u00e7 \u015firketinin stratejik belkemi\u011fidir. Bu disiplin, uluslararas\u0131 k\u0131lavuzlara uyarak her ilac\u0131n kan\u0131tlanm\u0131\u015f, g\u00fcvenilir ve emniyetli olmas\u0131n\u0131 sa\u011flar.<\/p>

\"\u0130la\u00e7
\u0130la\u00e7 Sekt\u00f6r\u00fcnde D\u00fczenleyici \u0130\u015fler.<\/strong><\/em><\/figcaption><\/figure>

\u00d6zellikle sahte ve standart alt\u0131 \u00fcr\u00fcnler gibi s\u00fcrekli tehditler g\u00f6z \u00f6n\u00fcnde bulunduruldu\u011funda, bu s\u00fcrecin b\u00fct\u00fcnl\u00fc\u011f\u00fc kritik \u00f6nem ta\u015f\u0131maktad\u0131r. Yak\u0131n tarihli bir DS\u00d6 raporuna g\u00f6re US$30,5 milyar<\/strong> her y\u0131l bu tehlikeli t\u0131bbi \u00fcr\u00fcnler i\u00e7in harcanmaktad\u0131r. Bu devasa rakam, k\u00fcresel tedarik zincirlerindeki b\u00fcy\u00fck bir g\u00fcvenlik a\u00e7\u0131\u011f\u0131n\u0131 vurgulamaktad\u0131r.<\/p>

D\u00fczenleyici \u0130\u015fler (RA), maksimum uyum ve koruma elde etmek i\u00e7in iki y\u00f6nl\u00fc stratejik bir \u00e7aba olarak ortaya \u00e7\u0131kmaktad\u0131r. Bilmek istiyorsan\u0131z bu makaleyi okumaya devam edin\u00a0<\/strong>\u0130la\u00e7ta ruhsatland\u0131rma i\u015flerinin ne oldu\u011fu, kimler taraf\u0131ndan y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fc ve i\u015finiz i\u00e7in neden bu kadar kritik oldu\u011fu.<\/p>

\u0130la\u00e7 Sekt\u00f6r\u00fcnde D\u00fczenleyici \u0130\u015fler Nedir?<\/strong><\/h2>

Ruhsatland\u0131rma i\u015fleri (RA), her ila\u00e7 \u00fcretim organizasyonunda \u00f6nemli bir departmand\u0131r. \u015eirket ile k\u00fcresel ila\u00e7 d\u00fczenleme makamlar\u0131 aras\u0131nda stratejik bir ba\u011flant\u0131 g\u00f6revi g\u00f6r\u00fcr. Departman\u0131n birincil rol\u00fc, her ilac\u0131n g\u00fcvenlik, kalite ve terap\u00f6tik performans i\u00e7in yasal ve bilimsel gereklilikleri kar\u015f\u0131lamas\u0131n\u0131 sa\u011flamakt\u0131r.<\/p>

RA departman\u0131, g\u00fcvenlik protokollerini denetlemenin \u00f6tesinde, laboratuvardan hastaya kadar olan t\u00fcm yolculu\u011fu y\u00f6netir. Bu, klinik \u00f6ncesi testlere ve klinik ara\u015ft\u0131rma ba\u015fvurular\u0131na rehberlik etmekten pazar izni i\u00e7in ruhsatland\u0131rma dosyalar\u0131n\u0131n haz\u0131rlanmas\u0131na kadar her \u015feye dahil olduklar\u0131 anlam\u0131na gelir.<\/p>

D\u00fczenleyici \u0130\u015fler Uzmanlar\u0131 kimlerdir?<\/strong><\/h2>

RA uzmanlar\u0131, eczac\u0131l\u0131k veya t\u0131p alan\u0131nda ge\u00e7mi\u015fleri olan ve genellikle \u00f6zel D\u00fczenleyici \u0130\u015fler (RA) sertifikalar\u0131na sahip uzmanlard\u0131r.<\/p>

Bilimsel \u00fcr\u00fcn verileri, d\u00fczenleyici yasalar ve uyumluluk y\u00f6nergeleri hakk\u0131nda g\u00fc\u00e7l\u00fc bilgiye sahiptirler. Ara\u015ft\u0131rma, \u00fcretim ve klinik ekipleriyle yak\u0131n i\u015fbirli\u011fi i\u00e7inde \u00e7al\u0131\u015fan RA uzmanlar\u0131, uyumlulu\u011fun korunmas\u0131na ve pazar onaylar\u0131n\u0131n g\u00fcvence alt\u0131na al\u0131nmas\u0131na yard\u0131mc\u0131 olur.<\/p>

Temel hedefleri, farmas\u00f6tik \u00fcr\u00fcnlerin WHO ve ABD FDA gibi k\u00fcresel d\u00fczenleyici otoriteler taraf\u0131ndan belirlenen standartlar\u0131 kar\u015f\u0131lamas\u0131n\u0131 sa\u011flamakt\u0131r.<\/p>

Kilit K\u00fcresel \u0130la\u00e7 D\u00fczenleme Otoriteleri<\/strong><\/h2>

\u0130la\u00e7 d\u00fczenleme kurumlar\u0131, bir ilac\u0131n kamu kullan\u0131m\u0131na uygunlu\u011funu onaylayan ulusal ve uluslararas\u0131 kurulu\u015flard\u0131r. \u0130la\u00e7lar da dahil olmak \u00fczere her ilac\u0131n kamu kullan\u0131m\u0131na uygun olmas\u0131n\u0131 sa\u011flamak i\u00e7in k\u00fcresel standartlar belirlerler. i\u0307la\u00e7 \u00fcreti\u0307mi\u0307<\/u><\/a>\u00a0s\u00fcreci, kalite standartlar\u0131n\u0131 kar\u015f\u0131lar ve g\u00fcvenli ve etkilidir.<\/p>

D\u00fczenleyici \u0130\u015flerin (RA) birincil rol\u00fc, \u015firket ile bu k\u00fcresel ila\u00e7 d\u00fczenleme otoriteleri aras\u0131nda temel irtibat ve terc\u00fcman olarak hareket etmektir.<\/p>

D\u00fcnyan\u0131n en etkili ajanslar\u0131ndan baz\u0131lar\u0131na ve nas\u0131l \u00e7al\u0131\u015ft\u0131klar\u0131na bir g\u00f6z atal\u0131m.<\/p>

1. D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (WHO)<\/strong><\/h3>

The\u00a0D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (DS\u00d6)<\/u><\/a>\u00a0farmas\u00f6tikler i\u00e7in k\u00fcresel normlar olu\u015fturan ve te\u015fvik eden uzmanla\u015fm\u0131\u015f bir Birle\u015fmi\u015f Milletler kurulu\u015fudur. Temel rol\u00fc, t\u00fcm ila\u00e7lar\u0131n y\u00fcksek kaliteli, g\u00fcvenli olmas\u0131n\u0131 ve ama\u00e7lanan etkiyi g\u00f6stermesini sa\u011flamakt\u0131r. DS\u00d6 a\u015fa\u011f\u0131dakiler gibi kritik standartlar belirler\u00a0\u0130yi \u00dcretim Uygulamalar\u0131 (GMP)<\/u><\/a>, Ulusal makamlar\u0131n d\u00fcnya \u00e7ap\u0131ndaki ila\u00e7 \u00fcretim tesislerini denetlemek ve belgelendirmek i\u00e7in kulland\u0131klar\u0131.<\/p>

2. ABD G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA)<\/strong><\/h3>

ABD.\u00a0<\/a>G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA)<\/u><\/a>\u00a0Amerika Birle\u015fik Devletleri'nde halk sa\u011fl\u0131\u011f\u0131n\u0131 korumaktan sorumlu federal d\u00fczenleyici kurumdur. Yetki alan\u0131 be\u015feri ve veteriner ila\u00e7lar\u0131, a\u015f\u0131lar, t\u0131bbi cihazlar, g\u0131da ve t\u00fct\u00fcn\u00fc kapsamaktad\u0131r. FDA \u00fcr\u00fcnleri d\u00fczenler, gerekli pazar onaylar\u0131n\u0131 verir ve sat\u0131lan t\u00fcm \u00fcr\u00fcnlerin g\u00fcvenli, g\u00fcvenilir ve federal yasalara uygun olmas\u0131n\u0131 sa\u011flamak i\u00e7in harekete ge\u00e7er.<\/p>

3. Avrupa \u0130la\u00e7 Ajans\u0131 (EMA)<\/strong><\/h3>

The\u00a0<\/a>Avrupa \u0130la\u00e7 Ajans\u0131 (EMA)<\/u><\/a>\u00a0be\u015feri ve veteriner ila\u00e7lar\u0131n\u0131n g\u00fcvenli\u011finin izlenmesi ve denetlenmesinden sorumlu Avrupa Birli\u011fi kurumudur. G\u00f6revleri, end\u00fcstriye bilimsel tavsiyelerde bulunmak, yenilik\u00e7ili\u011fi te\u015fvik etmek ve \u00fcr\u00fcn ya\u015fam d\u00f6ng\u00fcs\u00fc boyunca ila\u00e7 g\u00fcvenli\u011fini izlemektir.<\/p>

4. Ulusal \u0130la\u00e7 D\u00fczenleme Kurumlar\u0131<\/strong><\/h3>

Ulusal ila\u00e7 d\u00fczenleme kurumlar\u0131, kendi \u00fclkelerinde sat\u0131lan ila\u00e7lar\u0131n ve ilgili \u00fcr\u00fcnlerin kalitesini ve g\u00fcvenli\u011fini izleyen yerel devlet kurumlar\u0131d\u0131r. \u00d6rnekler \u015funlar\u0131 i\u00e7erir\u00a0<\/a>Sa\u011fl\u0131k Kanada<\/u><\/a>, Japonya \u0130la\u00e7 ve T\u0131bbi Cihaz Kurumu\u00a0<\/a>(PMDA)<\/u><\/a>, ve Birle\u015fik Krall\u0131k \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu\u00a0<\/a>(MHRA).<\/u><\/a><\/p>

D\u00fczenleyici \u0130\u015fleri Y\u00f6netmek: Sorumluluklar ve S\u00fcre\u00e7ler<\/strong><\/h2>

D\u00fczenleyici i\u015fler uzmanlar\u0131, bir ila\u00e7 kurulu\u015funun t\u00fcm ya\u015fam d\u00f6ng\u00fcs\u00fc y\u00f6netiminin bel kemi\u011fidir. API onay\u0131ndan \u00fcr\u00fcn\u00fcn nihai pazar iznine kadar, her profesyonel eylemin yasal olarak uyumlu olmas\u0131ndan sorumludurlar. \u0130\u015fte onlar\u0131n kapsaml\u0131 rollerini tan\u0131mlayan baz\u0131 temel sorumluluklar:<\/p>

1. \u0130la\u00e7 Etkin Maddesi G\u00f6nderimleri<\/strong><\/h3>

\u0130la\u00e7 \u00fcretimindeki ilk ad\u0131m, API'ler i\u00e7in yasal uygunlu\u011fu sa\u011flamakt\u0131r. D\u00fczenleyici \u0130\u015fler uzmanlar\u0131 a\u015fa\u011f\u0131dakiler gibi temel belgeleri haz\u0131rlar ve sunar\u00a0<\/a>ila\u00e7 ana dosyalar\u0131 (DMF'ler)<\/u><\/a>,\u00a0<\/strong>bo\u015fluk analizi ve s\u00fcrd\u00fcr\u00fclebilirlik sertifikalar\u0131. Bu, kulland\u0131\u011f\u0131n\u0131z API'lerin en y\u00fcksek kalitede oldu\u011funu ve uluslararas\u0131 standartlara uygun olarak \u00fcretildi\u011fini kan\u0131tlamak i\u00e7in gereklidir.<\/p>

2. Uyum ve Kalite G\u00fcvencesi<\/strong><\/h3>

\u0130la\u00e7 \u00fcretiminde uyumluluk ve kalite g\u00fcvencesi hasta g\u00fcvenli\u011fi \u00fczerinde do\u011frudan bir etkiye sahiptir. D\u00fczenleyici i\u015fler uzmanlar\u0131, t\u00fcm \u00fcr\u00fcnlerin ve s\u00fcre\u00e7lerin a\u015fa\u011f\u0131dakiler gibi kat\u0131 uluslararas\u0131 d\u00fczenlemelere uygun oldu\u011funu do\u011frular\u00a0<\/a>\u0130yi \u00dcretim Uygulamalar\u0131 (GMP)<\/u><\/a>\u00a0Ve\u00a0<\/a>\u0130yi Klinik Uygulamalar\u0131 (GCP)<\/u><\/a>.<\/p>

Ayr\u0131ca, \u00fcretim s\u00fcrecinin a\u015fa\u011f\u0131dakileri takip etmesini sa\u011flarlar\u00a0<\/a>\u0130la\u00e7 end\u00fcstrisindeki standart i\u015fletim prosed\u00fcrleri (SOP'ler)<\/u><\/a>\u00a0ve makine ve tesislerin istenen kalite ve do\u011frulama standartlar\u0131n\u0131 kar\u015f\u0131lamas\u0131.<\/p>

3. Klinik Ara\u015ft\u0131rmalar ve G\u00f6nderimler<\/strong><\/h3>

RA uzmanlar\u0131, kapsaml\u0131 d\u00fczenleyici stratejiler geli\u015ftirdikleri ve uyumlu klinik ara\u015ft\u0131rma tasar\u0131m\u0131 konusunda tavsiyelerde bulunduklar\u0131 i\u00e7in klinik a\u015faman\u0131n ayr\u0131lmaz bir par\u00e7as\u0131d\u0131r.<\/p>

gibi belgelerin olu\u015fturulmas\u0131ndan sorumludurlar. Ara\u015ft\u0131rma Ama\u00e7l\u0131 Yeni \u0130la\u00e7<\/span><\/a> (IND) ba\u015fvurusu yaparak insan deneylerine ba\u015flar. Ekip ayr\u0131ca FDA gibi sa\u011fl\u0131k otoriteleri taraf\u0131ndan nihai \u00fcr\u00fcn onay\u0131 i\u00e7in kapsaml\u0131 Yeni \u0130la\u00e7 Ba\u015fvurusunu (NDA) haz\u0131rlar.<\/p>

4. Piyasa Onay\u0131 ve Yetkilendirme<\/strong><\/h3>

Klinik ara\u015ft\u0131rmalardan sonra, pazar iznini g\u00fcvence alt\u0131na almak da kritik bir g\u00f6revdir. RA uzmanlar\u0131, Ortak Teknik Belge (CTD), bilimsel ara\u015ft\u0131rma, klinik d\u0131\u015f\u0131 \u00e7al\u0131\u015fma sonu\u00e7lar\u0131 ve kapsaml\u0131 klinik veriler dahil olmak \u00fczere ilgili t\u00fcm bilgileri bir araya getirir.<\/p>

Bu kapsaml\u0131 dosya, hem yerel hem de uluslararas\u0131 makamlar\u0131n gereksinimlerini kar\u015f\u0131lamak ve \u015firketin kamu pazar\u0131na eri\u015fim durumunu olu\u015fturmak i\u00e7in gereklidir.<\/p>

5. Yetkili Makamlarla \u0130rtibat ve \u0130leti\u015fim<\/strong><\/h3>

Mevzuat departman\u0131, \u015firketler ile Avrupa Komisyonu gibi kilit d\u00fczenleyici kurumlar aras\u0131ndaki birincil temas noktas\u0131d\u0131r. FDA ve EMA.<\/span><\/a><\/p>

Bu profesyoneller basit yaz\u0131\u015fmalardan profesyonel m\u00fczakerelere kadar sorular\u0131 y\u00f6netir, eksiklik mektuplar\u0131na yan\u0131t verir ve \u00fcr\u00fcn\u00fcn gerekli unsurlar\u0131n\u0131 tart\u0131\u015f\u0131r.<\/p>

6. Pazar Sonras\u0131 Y\u00f6netim ve Ya\u015fam D\u00f6ng\u00fcs\u00fc Uyumlulu\u011fu<\/strong><\/h3>

\u0130la\u00e7 onay ald\u0131ktan sonra, ruhsatland\u0131rma ekipleri \u00fcr\u00fcn\u00fcn \u00f6mr\u00fcn\u00fc pazar sonras\u0131 y\u00f6netim ve ya\u015fam d\u00f6ng\u00fcs\u00fc uyumlulu\u011fu yoluyla y\u00f6netmek zorundad\u0131r. \u00d6nemli bir bile\u015fen, hasta sa\u011fl\u0131\u011f\u0131n\u0131 korumak i\u00e7in s\u00fcrekli g\u00fcvenlik raporlamas\u0131 ve advers olay verilerinin denetlenmesini i\u00e7eren farmakovijilanst\u0131r.<\/p>

Ya\u015fam d\u00f6ng\u00fcs\u00fc uyumlulu\u011fu, onayl\u0131 \u00fcr\u00fcnde sonradan yap\u0131lan her de\u011fi\u015fiklik i\u00e7in karma\u015f\u0131k varyasyonlar\u0131n dosyalanmas\u0131n\u0131 i\u00e7erir. Bu gerekli de\u011fi\u015fiklikler, \u00fcretim yerinde bir de\u011fi\u015fiklik, revize edilmi\u015f bir terap\u00f6tik endikasyon veya nihai \u00fcr\u00fcn etiketlemesinde bir g\u00fcncelleme i\u00e7erebilir.<\/p>

Mevzuata Uyumsuzluk Riskleri<\/strong><\/h2>

Farmas\u00f6tik mevzuat uyumlulu\u011funun tart\u0131\u015f\u0131lmaz standartlar\u0131 vard\u0131r ve herhangi bir zay\u0131f halka ciddi sonu\u00e7lara yol a\u00e7abilir. \u0130la\u00e7 ya\u015fam d\u00f6ng\u00fcs\u00fc i\u00e7inde g\u00f6zetimdeki k\u00fc\u00e7\u00fck bir ihmal bile a\u011f\u0131r para cezalar\u0131na, \u00fcr\u00fcn geri \u00e7a\u011f\u0131rmalar\u0131na ve cezalara yol a\u00e7abilir. \u0130\u015fte b\u00f6yle:<\/p>

Risk No 1: Halk Sa\u011fl\u0131\u011f\u0131 Etkisi<\/strong><\/h3>

Halk, standart d\u0131\u015f\u0131 veya sahte ila\u00e7lar\u0131n ilk ve en savunmas\u0131z kurban\u0131d\u0131r. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131'na g\u00f6re DS\u00d6<\/span><\/a>, yakla\u015f\u0131k olarak\u00a0<\/a>her on ila\u00e7tan biri<\/u><\/a>\u00a0d\u00fc\u015f\u00fck ve orta gelirli \u00fclkelerde standartlar\u0131n alt\u0131nda veya tahrif edilmi\u015f durumdad\u0131r. Bu t\u00fcr ila\u00e7lar, \u00f6zellikle \u00f6ks\u00fcr\u00fck \u015furuplar\u0131 veya s\u0131tma ila\u00e7lar\u0131 gibi kritik ila\u00e7larda tedavi ba\u015far\u0131s\u0131zl\u0131\u011f\u0131na, hastal\u0131\u011f\u0131n ilerlemesine ve hatta \u00f6l\u00fcme yol a\u00e7maktad\u0131r.<\/p>

Risk No 2: Geciken\/\u0130nkar Edilen Onaylar<\/strong><\/h3>

Yeni bir ilac\u0131 piyasaya s\u00fcrmek zaten on y\u0131ll\u0131k bir s\u00fcre\u00e7. Genellikle 10 ila 15 y\u0131l s\u00fcrebilir<\/strong> \u0130lk ara\u015ft\u0131rmadan t\u00fcm klinik test a\u015famalar\u0131ndan ge\u00e7tikten sonra nihai pazar mevcudiyetine kadar. Herhangi bir ciddi mevzuat ihlali veya dok\u00fcmantasyon kusuru, pazar onay\u0131n\u0131 daha da geciktirebilir veya tamamen reddedebilir.<\/p>

Risk No 3: Para Cezalar\u0131 ve Yasal \u0130\u015flem<\/strong><\/h3>

Sahte veya standartlar\u0131n alt\u0131nda ila\u00e7 \u00fcretmek ve satmak neredeyse t\u00fcm \u00fclkelerde a\u011f\u0131r bir su\u00e7tur. \u00d6rne\u011fin, ABD'de sahte ila\u00e7 satmak ya da da\u011f\u0131tmak 10 y\u0131la kadar hapis ve para cezas\u0131na yol a\u00e7abilir. $250,000<\/strong> bireyler i\u00e7in para cezas\u0131. Bu cezalar, h\u00fck\u00fcmetlerin kamu sa\u011fl\u0131\u011f\u0131n\u0131 tehlikeye atan ihlalleri ele alma ciddiyetinin alt\u0131n\u0131 \u00e7izmektedir.<\/p>

\u00dcr\u00fcn\u00fcn\u00fcz\u00fc Uyumluluk ve Yenilikle G\u00fcvence Alt\u0131na Al\u0131n<\/strong><\/h2>

\u0130la\u00e7 sekt\u00f6r\u00fcnde D\u00fczenleyici \u0130\u015flerin (RA) do\u011frudan sorumlulu\u011funda olmasa da, \u00fcretim ekipmanlar\u0131n\u0131n kalitesi uyumlulu\u011fun s\u00fcrd\u00fcr\u00fclmesinde \u00e7ok \u00f6nemli bir rol oynar.<\/p>

G\u00fcvenilir, onaylanm\u0131\u015f ve bak\u0131m\u0131 iyi yap\u0131lm\u0131\u015f ekipman olmadan, en \u00f6zenli uyum ve kalite \u00e7abalar\u0131 bile ba\u015far\u0131s\u0131z olabilir. Bu nedenle, bir RA i\u015fe alman\u0131n yan\u0131 s\u0131ra, y\u00fcksek kaliteli, uyumlu \u00fcretim sistemlerine yat\u0131r\u0131m yapmak ve Finetech gibi g\u00fcvenilir ekipman tedarik\u00e7ileriyle ortakl\u0131k kurmak \u00e7ok \u00f6nemlidir.<\/p>

\u015eu anda Finetech<\/u><\/a>, geli\u015fmi\u015f teknik \u00e7\u00f6z\u00fcmler sunman\u0131n \u00f6tesine ge\u00e7iyoruz. Kapsaml\u0131 yerinde e\u011fitimle ekibinizi g\u00fc\u00e7lendiriyor ve \u00e7\u0131kt\u0131y\u0131 en \u00fcst d\u00fczeye \u00e7\u0131karman\u0131za, uyumlulu\u011fu s\u00fcrd\u00fcrmenize ve uzun vadeli \u00fcretim m\u00fckemmelli\u011fine ula\u015fman\u0131za yard\u0131mc\u0131 oluyoruz. Finetech ile bug\u00fcn ileti\u015fime ge\u00e7in ve uyumlu, yenilik\u00e7i \u00fcretimde gelece\u011finizi g\u00fcvence alt\u0131na al\u0131n.<\/p>

Telif Hakk\u0131 Uyar\u0131s\u0131:\u00a0<\/b><\/h2>

Finetech Group'un \u00f6nceden a\u00e7\u0131k yaz\u0131l\u0131 onay\u0131 olmadan bu web sitesindeki herhangi bir i\u00e7eri\u011fi \u00e7o\u011faltamaz, de\u011fi\u015ftiremez, yay\u0131nlayamaz, g\u00f6r\u00fcnt\u00fcleyemez, iletemez veya herhangi bir \u015fekilde istismar edemezsiniz veya bu t\u00fcr i\u00e7eri\u011fi herhangi bir veritaban\u0131 olu\u015fturmak i\u00e7in kullanamazs\u0131n\u0131z. \u0130\u00e7eri\u011fi kullanma izni i\u00e7in l\u00fctfen ileti\u015fime ge\u00e7in: info@pharmamachinecn.com<\/span><\/a><\/p>

Yasal Uyar\u0131:<\/b><\/h2>

Bu makalede yer alan bilgiler yaln\u0131zca genel bilgilendirme ama\u00e7l\u0131d\u0131r. \u015eirket, herhangi bir bilginin do\u011frulu\u011funu, g\u00fcncelli\u011fini veya eksiksizli\u011fini garanti etmez ve \u015eirket, bu makalenin i\u00e7eri\u011findeki hatalar veya eksiklikler i\u00e7in hi\u00e7bir sorumluluk kabul etmez.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Regulatory Affairs (RA) is the strategic backbone of a pharmaceutical company. This discipline ensures every medicine is proven, reliable, and […]<\/p>\n","protected":false},"author":1,"featured_media":11155,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[60],"tags":[],"class_list":["post-11122","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-equipment"],"acf":[],"_links":{"self":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts\/11122","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/comments?post=11122"}],"version-history":[{"count":10,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts\/11122\/revisions"}],"predecessor-version":[{"id":12936,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/posts\/11122\/revisions\/12936"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/media\/11155"}],"wp:attachment":[{"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/media?parent=11122"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/categories?post=11122"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmamachinecn.com\/tr\/wp-json\/wp\/v2\/tags?post=11122"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}